Breaking News

WuXi Launches CAR-T Cell Therapy Platform

Will enable biotechnology companies and researchers to accelerate the development, manufacturing and release of cell and gene therapies for patients

By: Contract Pharma

Contract Pharma Staff

WuXi Advanced Therapies, a global contract development and manufacturing organization (CDMO) offering end-to-end contract services for the advanced therapies industry, has expanded its service capabilities to offer a fully integrated Closed Process CAR-T Cell Therapy Platform. This new platform will accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.   “We are excited to launch this world-class Closed Process CAR-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters